US Autoinjectors Market

The report "US Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Forecast to 2030", is projected to expand to a value of USD 1.45 billion in 2030 from USD 0.65 billion in 2024, with a significant CAGR of 14.2%. The autoinjector finished formulations market is projected to surge to a value of  USD 77.84 billion in 2030 from USD 37.28 billion in 2024, growing at a CAGR of 13.1%. Some of the prominent factors driving the growth of the market in the US are adequate reimbursement policies, a rise in the number of regulatory approvals for autoinjectors, increasing demand for self-administration of biologics, rising prevalence of chronic diseases such as diabetes and rheumatoid arthritis, growing preference for patient-centric drug delivery solutions and shift towards prefilled autoinjectors for convenience and safety, along with strategic partnerships between pharmaceutical companies and device manufacturers.

US autoinjectors market- Forecast to 2030. Browse over 150 tables, 50 figures, and an in-depth TOC on the US autoinjectors market report. Early buyers will receive 10% customization on the report.

To know about the assumptions considered for the study download the pdf brochure

Rheumatoid Arthritis accounted for the dominant share of the US autoinjectors market in 2023.

Based on the therapy area, the autoinjectors market is divided into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, obesity, and other therapy areas. In 2023, the rheumatoid arthritis segment dominated the autoinjectors market, and the obesity segment is anticipated to grow at the highest CAGR during the forecast period in US. The growing prevalence of rheumatoid arthritis and the availability of autoinjectors for the treatment of this condition are some of the major factors driving the growth of the market. The obesity segment is likely to grow at a faster pace owing to the launch of novel products and the rise in the adoption of autoinjectors for weight management.

Additionally, the increasing number of FDA approvals for autoinjectors in the US is expected to drive market expansion, ensuring wider availability of advanced drug delivery solutions for patients.

Reusable autoinjectors segment is likely to grow at a significant CAGR during the forecast period in US autoinjectors devices market.

Based on usage, the autoinjectors market is categorized into reusable and disposable autoinjectors. In 2023, the disposable segment accounted for the fastest-growing share of the usage segment of the autoinjectors market in the US. The easy handling, compatible self-administration, and decreased risk of cross-contamination are driving the growth of the disposable autoinjectors market. Innovations in reusable autoinjectors, such as ergonomic designs, digital interfaces, and enhanced safety features, are contributing to the rising adoption of reusable autoinjectors in developing countries.

Furthermore, in the US, growing regulatory support and reimbursement policies for self-injection devices are expected to further accelerate the adoption of both disposable and reusable autoinjectors.

Autoinjectors market players for devices include Becton, Dickinson and Company (BD) (US), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc. (US), Owen Mumford Ltd. (UK), Kaleo, Inc. (US), Jabil, Inc. (US), Congruence Medical Solutions LLC (US). Some of the major market players for finished formulations covered in this chapter include Abbvie Inc. (US), Eli Lilly and Company (US), Amgen Inc. (US), and Jonhson & Jonhson Services Inc. (US).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/